Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track

More than a year after Gamida Cell slimmed down its workforce, the biotech has again resorted to laying off staff to keep the long-delayed plans for its blood cancer treatment omidubicel on the road.